These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17259740)

  • 1. Secondary hyperparathyroidism is associated with higher cost of care among chronic kidney disease patients with cardiovascular comorbidities.
    Khan S
    Nephron Clin Pract; 2007; 105(4):c159-64. PubMed ID: 17259740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients.
    Schumock GT; Andress DL; Marx SE; Sterz R; Joyce AT; Kalantar-Zadeh K
    Nephron Clin Pract; 2009; 113(1):c54-61. PubMed ID: 19590235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J; López-Gómez JM; Aljama P
    Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
    Danese MD; Kim J; Doan QV; Dylan M; Griffiths R; Chertow GM
    Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
    Collins AJ
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs.
    Wei SY; Chang YY; Mau LW; Lin MY; Chiu HC; Tsai JC; Huang CJ; Chen HC; Hwang SJ
    Nephrology (Carlton); 2010 Feb; 15(1):108-15. PubMed ID: 20377778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher incidence of cholelithiasis in chronic renal failure patients with secondary hyperparathyroidism undergoing peritoneal dialysis.
    Barut I; Tarhan OR; Baykal B; Demir M; Celikbas B
    Ren Fail; 2007; 29(4):453-7. PubMed ID: 17497468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dialysis care, cardiovascular disease, and costs in end-stage renal disease in Brazil.
    Sesso R; da Silva CB; Kowalski SC; Manfredi SR; Canziani ME; Draibe SA; Elgazzar HA; Ferraz MB
    Int J Technol Assess Health Care; 2007; 23(1):126-30. PubMed ID: 17234026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients.
    Schumock GT; Andress D; E Marx S; Sterz R; Joyce AT; Kalantar-Zadeh K
    Curr Med Res Opin; 2008 Nov; 24(11):3037-48. PubMed ID: 18826748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How abnormal calcium, phosphate, and parathyroid hormone relate to cardiovascular disease.
    Bro S
    Nephrol Nurs J; 2003 Jun; 30(3):275-81; quiz 282-3. PubMed ID: 12861895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic kidney disease: the distribution of health care dollars.
    St Peter WL; Khan SS; Ebben JP; Pereira BJ; Collins AJ
    Kidney Int; 2004 Jul; 66(1):313-21. PubMed ID: 15200439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
    Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
    Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of hyperparathyroidism in advanced stages of chronic kidney disease.
    El Kossi M; Rana A; El Nahas M
    Saudi J Kidney Dis Transpl; 2009 Jul; 20(4):623-7. PubMed ID: 19587504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular changes in chronic renal disease patients with secondary hyperparathyroidism.
    Bortotolotto LA; Costa-Hong V; Jorgetti V; Consolim-Colombo F; Rosa K; Silva BC; Krieger EM; De Lima JJ
    J Nephrol; 2007; 20(1):66-72. PubMed ID: 17347976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of advanced chronic kidney disease on in-hospital mortality following percutaneous coronary intervention for acute myocardial infarction.
    Vasu S; Gruberg L; Brown DL
    Catheter Cardiovasc Interv; 2007 Nov; 70(5):701-5. PubMed ID: 17932900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.